Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 10/20 | 0.69 |
| ▸ | PIM1 | P11309 | 2/20 | 0.53 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.53 |
| ▸ | IGF1R | P08069 | 2/20 | 0.49 |
| ▸ | CCNA2 | P20248 | 7/20 | 0.49 |
| ▸ | CDK2 | P24941 | 7/20 | 0.49 |
| ▸ | CCNA1 | P78396 | 7/20 | 0.49 |
| ▸ | PLK1 | P53350 | 3/20 | 0.48 |
| ▸ | PLK3 | Q9H4B4 | 2/20 | 0.47 |
| ▸ | PLK2 | Q9NYY3 | 2/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12466264 | 0.95 | TTK (0.62) | TTKPIM1IGF1RCCNA2CDK2 | |
| SCHEMBL12466544 | 0.88 | TTK (0.62) | TTKPIM1IGF1RCCNA2CDK2 | |
| SCHEMBL12466647 | 0.88 | TTK (0.58) | TTKPIM1IGF1RCCNA2CDK2 | |
| SCHEMBL15364067 | 0.86 | TTK (0.80) | TTKCCNA2CDK2CCNA1PLK1 | |
| SCHEMBL12698357 | 0.82 | TTK (1.00) | TTKPIM1PIM2CCNA2CDK2 | |
| SCHEMBL12499416 | 0.81 | TTK (0.83) | TTKPIM1PIM2CCNA2CDK2 | |
| SCHEMBL15377595 | 0.81 | TTK (1.00) | TTKPIM1PIM2CCNA2CDK2 | |
| SCHEMBL12466399 | 0.81 | TTK (0.73) | TTKCCNA2CDK2CCNA1PLK1 | |
| SCHEMBL12499340 | 0.81 | TTK (0.80) | TTKPIM1PIM2CCNA2CDK2 | |
| SCHEMBL12698407 | 0.79 | TTK (0.70) | TTKPIM1PIM2IGF1RCCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2668190-B1 | TRICYCLIC PYRROLO DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2016-08-17 | — | — | EP | disclosed |
| US-9309253-B2 | Tricyclic pyrrolo derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-04-12 | — | — | US | disclosed |
| US-9309253-B2 | Tricyclic pyrrolo derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-04-12 | — | — | US | disclosed |
| US-9309253-B2 | Tricyclic pyrrolo derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-04-12 | — | — | US | disclosed |
| US-20150141408-A1 | TRICYCLIC PYRROLO DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-05-21 | — | — | US | disclosed |
| US-20150141408-A1 | TRICYCLIC PYRROLO DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-05-21 | — | — | US | disclosed |
| US-20150141408-A1 | TRICYCLIC PYRROLO DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-05-21 | — | — | US | disclosed |
| US-8975267-B2 | Tricyclic pyrrolo derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-03-10 | — | — | US | disclosed |
| EP-2668190-A1 | TRICYCLIC PYRROLO DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2013-12-04 | — | — | EP | disclosed |
| US-20130296305-A1 | TRICYCLIC PYRROLO DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-11-07 | — | — | US | disclosed |
| WO-2012101032-A1 | TRICYCLIC PYRROLO DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141408-A1 | TRICYCLIC PYRROLO DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | MAP3K1, MAP3K20, MAP3K6 | TTK 257/4885PIM1 522/4885PIM2 533/4885 |
| US-20130296305-A1 | TRICYCLIC PYRROLO DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | MAP3K1, MAP3K20, MAP3K5 | TTK 313/4885PIM1 514/4885PIM2 548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.